Literature DB >> 15530254

A clinician's guide to hereditary colon cancer.

Ellen T Matloff1, Karina L Brierley, Christina M Chimera.   

Abstract

Approximately 10% of patients diagnosed with colorectal cancer are at risk for a hereditary form of the disease. At-risk patients can be offered genetic counseling and testing to determine whether they carry a detectable mutation for such a syndrome. If so, this information provides the clinician with valuable data about the patient's risk for other cancers, and what further surveillance and risk reduction options should be incorporated into the management plan. Mutation identification within a family also makes it possible for other family members to learn if they are at risk for the same syndrome. There are many hereditary colorectal cancer syndromes, and the clinician must know what essential information should be elicited from a family history and which patients should be referred for genetic counseling and testing.

Entities:  

Mesh:

Year:  2004        PMID: 15530254     DOI: 10.1097/00130404-200409000-00002

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  6 in total

1.  Molecular diagnostics. At the nexus of individualized medicine, health care delivery, and public policy.

Authors:  Scott A Waldman; Andre Terzic
Journal:  Clin Transl Sci       Date:  2009-02       Impact factor: 4.689

2.  Where medicine, business, and public policy intersect.

Authors:  Chantell L Wilson; Stephanie Schultz; Scott A Waldman
Journal:  Biotechnol Healthc       Date:  2007-02

3.  Mitotic checkpoint kinase Mps1/TTK predicts prognosis of colon cancer patients and regulates tumor proliferation and differentiation via PKCα/ERK1/2 and PI3K/Akt pathway.

Authors:  Li Zhang; Baofei Jiang; Ni Zhu; Mingyue Tao; Yali Jun; Xiaofei Chen; Qilong Wang; Chao Luo
Journal:  Med Oncol       Date:  2019-11-13       Impact factor: 3.064

4.  Fas/CD95 deficiency in ApcMin/+ mice increases intestinal tumor burden.

Authors:  Hector Guillen-Ahlers; Mark A Suckow; Francis J Castellino; Victoria A Ploplis
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

5.  Sulindac treatment alters collagen and matrilysin expression in adenomas of ApcMin/+ mice.

Authors:  Hector Guillen-Ahlers; Steven A Buechler; Mark A Suckow; Francis J Castellino; Victoria A Ploplis
Journal:  Carcinogenesis       Date:  2008-05-21       Impact factor: 4.944

6.  Tank Binding Kinase 1 modulates spindle assembly checkpoint components to regulate mitosis in breast and lung cancer cells.

Authors:  Meenu Maan; Neha Jaiswal Agrawal; Jaya Padmanabhan; Christelle Colin Leitzinger; Yainyrette Rivera-Rivera; Harold I Saavedra; Srikumar P Chellappan
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2020-12-11       Impact factor: 4.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.